209

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2004, 15:42:53 ; Search time 40 Seconds
(without alignments)
472.212 Million cell updates/sec

Title: US-09-786-260-1
Perfect score: 644
Sequence: 1 MKVLISSLLLLLPLMLMSMV.....SRACQQFLKQCQLRSFALPL 119

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	644	100.0	119	21	AAB34728	Human secreted pro
2	644	100.0	119	21	AAY82453	Human TGC-440 secr
3	644	100.0	119	21	AAY87317	Human signal pepti
4	644	100.0	119	21	AAY66668	Membrane-bound pro
5	644	100.0	119	22	AAU29093	Human PRO polypept
6	644	100.0	119	22	AAG63977	Amino acid sequenc
7	644	100.0	119	22	AAB87538	Human PRO842. Hom
8	644	100.0	119	22	AAB65191	Human PRO842 (UNQ4
9	644	100.0	119	23	ABP54931	Human cytokine PRO
10	644	100.0	119	23	ABG95863	Human secreted/tra
11	644	100.0	119	24	ABU71181	Human PRO842 prote
12	644	100.0	119	24	ABU71518	Human secreted pol
13	644	100.0	119	24	ABU71964	Novel human secret
14	644	100.0	119	24	ABU72121	Human PRO polypept
15	644	100.0	119	24	ABU65638	Human secreted/tra
16	644	100.0	119	24	ABU65971	Novel human secret
17	644	100.0	119	24	ABU67475	Human secreted/tra
18	644	100.0	119	24	ABU65333	Human PRO polypept
19	644	100.0	119	24	ABU59084	Novel human secret
20	644	100.0	119	24	ABU59231	Human secreted/tra
21	644	100.0	119	24	ABU59380	Novel human secret
22	644	100.0	119	24	ABU60515	Human secreted/tra
23	644	100.0	119	24	ABU58006	Human PRO polypept
24	644	100.0	119	24	ABU58469	Human PRO polypept
25	644	100.0	119	24	ABU58937	Human sectreted/tr
26	644	100.0	119	24	ABU56005	Human secreted/tra
27	644	100.0	119	24	ABU57000	Human PRO polypept
28	644	100.0	119	24	ABU13897	Human PRO842 polyp
29	644	100.0	119	24	ABU10579	Human secreted/tra
30	644	100.0	119	24	ABU10852	Human PRO polypept
31	548	85.1	97	21	AAY82454	Mature human TGC-4
32	527	81.8	93	19	AAW83953	Polypeptide encode
33	456	70.8	119	21	AAY82457	Mouse TGC-440 secr
34	386	59.9	97	21	AAY82458	Mature mouse TGC-4
35	386	59.9	119	21	AAY82455	Rat TGC-440 secret
36	358	55.6	69	20	AAY11732	Human 5' EST secre
37	342	53.1	97	21	AAY82456	Mature rat TGC-440
38	296	46.0	64	19	AAW83938	Human secreted pro
39	225	34.9	48	20	AAY11731	Human 5' EST secre
40	78.5	12.2	191	22	AAU66308	Propionibacterium
41	73.5	11.4	70	10	AAP91996	Part of chick vita
42	73.5	11.4	70	14	AAR43657	Chicken vitamin D
43	71.5	11.1	108	23	AAO21337	Arabidopsis thalia
44	71	11.0	330	22	ABG25331	Novel human diagno
45	71	11.0	1798	19	AAW50896	Human laminin B2 c

ALIGNMENTS

RESULT 1
AAB34728
ID AAB34728 standard; Protein; 119 AA.
XX
AC AAB34728;
XX
DT 26-JAN-2001 (first entry)
XX
DE Human secreted protein encoded by DNA clone vq8 1.
XX
KW Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;
KW systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;
KW haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;
KW Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer;
KW contraceptive; infection; growth inhibition; hyperproliferative disorder;
KW psoriasis.
XX
OS Homo sapiens.
XX
PN WO200055375-A1.
XX
PD 21-SEP-2000.
XX
PF 17-MAR-2000; 2000WO-US07285.
XX
PR 17-MAR-1999; 99US-0124808.
PR 17-MAR-1999; 99US-0124916.
PR 17-AUG-1999; 99US-0149639.
PR 01-OCT-1999; 99US-0157247.
PR 29-NOV-1999; 99US-0167824.
PR 15-FEB-2000; 2000US-0182711.
XX
PA (ALPH-) ALPHAGENE INC.
XX
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR WPI; 2000-638211/61.
DR N-PSDB; AAC59829.
XX
PT Novel proteins and polypeptides useful for the treatment of e.g
PT multiple sclerosis, systemic lupus erythmatosus, rheumatoid arthritis,
PT cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and
PT ulcers -
XX
PS Claim 92; Page 441-442; 493pp; English.
XX
CC This invention relates to 59 human secreted proteins and the nucleotide
CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745
CC represent the proteins and their encoding nucleotide sequences, and
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes
CC for the DNA sequences are represented by sequences AAC59847-C59596. The
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,
CC cerebroprotective, haemostatic, vulnerary, cytostatic, antipsoriatic,
CC antibacterial, virucide, and fungicide activity. The proteins and
CC nucleotide sequences are useful as nutritional sources or supplements
CC and in research. The proteins are useful for treating immune deficiency

CC and disorders, which may be genetic or resulting from infections,
CC autoimmune disorders such as multiple sclerosis, systemic lupus
CC erythmatosus, rheumatoid arthritis, and for treating myeloid or lymphoid
CC cell deficiencies such as anaemias by regulating haematopoiesis. The
CC proteins are also useful in compositions for bone, cartilage, tendon,
CC ligament and/or nerve tissue growth or regeneration, for wound healing,
CC tissue repair and replacement and in the treatment of wounds, incisions
CC and ulcers. Other uses include in the treatment of central and
CC peripheral nervous system and neuropathies such as Alzheimer's and
CC Parkinson's diseases and Shy-Drager syndrome, and mechanical and
CC traumatic disorders, such as spinal cord disorders, head trauma and
CC stroke. The proteins may also be used as a contraceptive, and for
CC treating coagulation disorders such as haemophilias. The protein and
CC nucleotide sequences with cadherin activity are useful for treating
CC cancer. Other uses for the protein include for inhibiting the growth,
CC infection or function of, or killing, infectious agents such as bacteria,
CC virus, fungi and other parasites, for effecting bodily characteristics
CC such as height, weight, hair colour, effecting biorhythms or cardiac
CC cycles or rhythms, effecting metabolism, catabolism, anabolism,
CC processing, utilization, storage or elimination of dietary fat, lipid,
CC protein, carbohydrate, vitamins, minerals, cofactors, effecting
CC behavioural characteristics, providing analgesic effects and for treating
CC hyperproliferative disorders such as psoriasis.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 2
AAY82453
ID AAY82453 standard; Protein; 119 AA.
XX
AC AAY82453;
XX
DT 30-JUN-2000 (first entry)
XX
DE Human TGC-440 secretory protein SEQ ID NO:1.
XX
KW TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
XX
OS Homo sapiens.

XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PF 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
DR N-PSDB; AAA08343, AAA08344.
XX
PT Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX
PS Claim 1; Fig 1; 86pp; Japanese.
XX
CC The present sequence represents a human secretory protein designated
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC encoding it can be used to treat, prevent and diagnose immunological,
CC lung, liver, kidney or gastrointestinal disorders and infectious
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX
SQ Sequence 119 AA;

  Query Match   100.0%; Score 644; DB 21; Length 119;
  Best Local Similarity   100.0%; Pred. No. 1.8e-66;
  Matches 119; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy   61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119

RESULT 3
AAY87317
ID AAY87317 standard; Protein; 119 AA.
XX
AC AAY87317;
XX
DT 11-MAY-2000 (first entry)
XX

DE Human signal peptide containing protein HSPP-94 SEQ ID NO:94.
XX
KW Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's diseases; ovulatory defect;
KW muscular dystrophy.
XX
OS Homo sapiens.
XX
PN WO200000610-A2.
XX
PD 06-JAN-2000.
XX
PF 25-JUN-1999; 99WO-US14484.
XX
PR 26-JUN-1998; 98US-0090762.
PR 31-JUL-1998; 98US-0094983.
PR 01-OCT-1998; 98US-0102686.
PR 11-DEC-1998; 98US-0112129.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
DR WPI; 2000-160673/14.
DR N-PSDB; AAZ98202.
XX
PT New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and
PT cardiovascular disease -
XX
PS Claim 1; Page 220-221; 327pp; English.
XX
CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can
CC be used in gene therapy. HSPPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSPP. Antagonists of
CC HSPP are used to treat or prevent disorders associated with increased
CC activity or function of HSPP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC nucleic acids can be used for the recombinant production of HSPP, for
CC detecting HSPP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense,

```
CC   triplex-forming or ribozyme therapeutics, for detecting related sequences
CC   or genetic variations, and for chromosomal mapping. HSPP are also used to
CC   raise specific antibodies (Ab) and to screen for agonists and
CC   antagonists (potential therapeutic agents). Ab are used to diagnose, or
CC   monitor, HSPP-related diseases (in usual immunoassays), as therapeutic
CC   antagonists, in competitive drug screens, and for purification of HSPP
CC   from natural sources.
XX
SQ   Sequence   119 AA;

  Query Match             100.0%;  Score 644;  DB 21;  Length 119;
  Best Local Similarity   100.0%;  Pred. No. 1.8e-66;
  Matches  119;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119


RESULT 4
AAY66668
ID   AAY66668 standard; protein; 119 AA.
XX
AC   AAY66668;
XX
DT   05-APR-2000  (first entry)
XX
DE   Membrane-bound protein PRO842.
XX
KW   Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW   pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS   Homo sapiens.
XX
PN   WO9963088-A2.
XX
PD   09-DEC-1999.
XX
PF   02-JUN-1999;   99WO-US12252.
XX
PR   02-JUN-1998;   98US-0087607.
PR   02-JUN-1998;   98US-0087609.
PR   02-JUN-1998;   98US-0087759.
PR   03-JUN-1998;   98US-0087827.
PR   04-JUN-1998;   98US-0088021.
PR   04-JUN-1998;   98US-0088025.
PR   04-JUN-1998;   98US-0088028.
PR   04-JUN-1998;   98US-0088029.
PR   04-JUN-1998;   98US-0088030.
PR   04-JUN-1998;   98US-0088033.
PR   04-JUN-1998;   98US-0088326.
PR   05-JUN-1998;   98US-0088167.
PR   05-JUN-1998;   98US-0088202.
```

PR 05-JUN-1998; 98US-0088212.
PR 05-JUN-1998; 98US-0088217.
PR 09-JUN-1998; 98US-0088655.
PR 10-JUN-1998; 98US-0088722.
PR 10-JUN-1998; 98US-0088730.
PR 10-JUN-1998; 98US-0088734.
PR 10-JUN-1998; 98US-0088738.
PR 10-JUN-1998; 98US-0088740.
PR 10-JUN-1998; 98US-0088741.
PR 10-JUN-1998; 98US-0088742.
PR 10-JUN-1998; 98US-0088810.
PR 10-JUN-1998; 98US-0088811.
PR 10-JUN-1998; 98US-0088824.
PR 10-JUN-1998; 98US-0088825.
PR 10-JUN-1998; 98US-0088826.
PR 11-JUN-1998; 98US-0088858.
PR 11-JUN-1998; 98US-0088861.
PR 11-JUN-1998; 98US-0088863.
PR 11-JUN-1998; 98US-0088876.
PR 12-JUN-1998; 98US-0089090.
PR 12-JUN-1998; 98US-0089105.
PR 16-JUN-1998; 98US-0089440.
PR 16-JUN-1998; 98US-0089512.
PR 16-JUN-1998; 98US-0089514.
PR 17-JUN-1998; 98US-0089532.
PR 17-JUN-1998; 98US-0089538.
PR 17-JUN-1998; 98US-0089598.
PR 17-JUN-1998; 98US-0089599.
PR 17-JUN-1998; 98US-0089600.
PR 17-JUN-1998; 98US-0089653.
PR 18-JUN-1998; 98US-0089801.
PR 18-JUN-1998; 98US-0089907.
PR 18-JUN-1998; 98US-0089908.
PR 19-JUN-1998; 98US-0089947.
PR 19-JUN-1998; 98US-0089948.
PR 19-JUN-1998; 98US-0089952.
PR 22-JUN-1998; 98US-0090246.
PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.

PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 02-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 07-JUL-1998; 98US-0091982.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.

PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
DR N-PSDB; AAZ65001.
XX
PT Membrane-bound proteins and related nucleotide sequences -
XX
PS claim 12; Fig 99; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
SQ Sequence 119 AA;

  Query Match 100.0%; Score 644; DB 21; Length 119;
  Best Local Similarity 100.0%; Pred. No. 1.8e-66;
  Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy 61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
    |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119

RESULT 5
AAU29093
ID AAU29093 standard; Protein; 119 AA.
XX
AC AAU29093;

XX
DT 18-DEC-2001 (first entry)
XX
DE Human PRO polypeptide sequence #70.
XX
KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200168848-A2.
XX
PD 20-SEP-2001.
XX
PF 28-FEB-2001; 2001WO-US06520.
XX
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 03-MAR-2000; 2000US-187202P.
PR 06-MAR-2000; 2000US-186968P.
PR 14-MAR-2000; 2000US-189320P.
PR 14-MAR-2000; 2000US-189328P.
PR 15-MAR-2000; 2000WO-US06884.
PR 21-MAR-2000; 2000US-190828P.
PR 21-MAR-2000; 2000US-191007P.
PR 21-MAR-2000; 2000US-191048P.
PR 21-MAR-2000; 2000US-191314P.
PR 28-MAR-2000; 2000US-192655P.
PR 29-MAR-2000; 2000US-193032P.
PR 29-MAR-2000; 2000US-193053P.
PR 30-MAR-2000; 2000WO-US08439.
PR 04-APR-2000; 2000US-194449P.
PR 04-APR-2000; 2000US-194647P.
PR 11-APR-2000; 2000US-195975P.
PR 11-APR-2000; 2000US-196000P.
PR 11-APR-2000; 2000US-196187P.
PR 11-APR-2000; 2000US-196690P.
PR 11-APR-2000; 2000US-196820P.
PR 18-APR-2000; 2000US-198121P.
PR 18-APR-2000; 2000US-198585P.
PR 25-APR-2000; 2000US-199397P.
PR 25-APR-2000; 2000US-199550P.
PR 25-APR-2000; 2000US-199654P.
PR 03-MAY-2000; 2000US-201516P.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 05-JUN-2000; 2000US-209832P.
PR 28-JUL-2000; 2000WO-US20710.
PR 22-AUG-2000; 2000US-0644848.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.

XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-602746/68.
DR N-PSDB; AAS45994.
XX
PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT presence of tumours, such as prostate and breast tumours, in mammals and
PT to screen for modulators of the compounds -
XX
PS Claim 11; Fig 140; 774pp; English.
XX
CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
CC The PRO polypeptides and their associated nucleic acids can be used to
CC detect the presence of a tumour in a mammal by comparing the level of
CC expression of a PRO polypeptide in a test sample of cells from the animal
CC and a control sample of normal cells, whereby a higher level of
CC expression in the test sample indicates the presence of a tumour in the
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
CC and rabbits but are preferably human. The polypeptides can be used to
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
CC when contacted with it. A specific polypeptide can be used to stimulate
CC the proliferation or differentiation of chondrocyte cells. The PRO
CC proteins can be used to determine the presence of tumours and also
CC susceptibility to tumour development, particularly adrenal, lung, colon,
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC can be used for genetic analysis of individuals with genetic disorders.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 6
AAG63977
ID AAG63977 standard; Protein; 119 AA.
XX
AC AAG63977;
XX
DT 13-NOV-2001 (first entry)
XX
DE Amino acid sequence of a human Lng104 polypeptide.
XX

KW Human; lung cancer specific gene; LSG; Lng104; lung cancer.
XX
OS Homo sapiens.
XX
PN WO200161055-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05674.
XX
PR 17-FEB-2000; 2000US-0183188.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Chen S, Sun Y, Macina RA;
XX
DR WPI; 2001-529917/58.
DR N-PSDB; AAH77949, AAH77951.
XX
PT New lung cancer specific gene for the treatment and diagnosis of lung
PT cancer -
XX
PS Claim 2; Page 115-116; 119pp; English.
XX
CC The present sequence is encoded by a human lung cancer specific gene
CC (LSG), and represents a polypeptide designated Lng104. LSGs are useful
CC in the treatment and diagnosis of lung cancer. The treatment of lung
CC cancer comprises the administration of a molecule which down regulates
CC the expression of an LSG. An immune response can be mounted against a
CC target cell expressing an LSG. Identification of potential therapeutic
CC agents for use in imaging and treating lung cancer which comprises
CC screening molecules for an ability to bind to or decrease expression
CC of an LSG relative to LSG in the absence of the agent where the ability
CC of a molecule to bind to the LSG or decrease expression of the LSG is
CC indicative of the molecule being useful in imaging and treating lung
CC cancer.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 7
AAB87538
ID AAB87538 standard; Protein; 119 AA.
XX
AC AAB87538;

XX
DT 15-MAY-2001 (first entry)
XX
DE Human PRO842.
XX
KW Human; PRO protein; mapping.
XX
OS Homo sapiens.
XX
PN WO200116318-A2.
XX
PD 08-MAR-2001.
XX
PF 24-AUG-2000; 2000WO-US23328.
XX
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 07-DEC-1999; 99US-0169495.
PR 09-DEC-1999; 99US-0170262.
PR 11-JAN-2000; 2000US-0175481.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 01-MAR-2000; 2000WO-US05601.
PR 03-MAR-2000; 2000US-0187202.
PR 25-APR-2000; 2000US-0199397.
PR 22-MAY-2000; 2000WO-US14042.
PR 05-JUN-2000; 2000US-0209832.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2001-183260/18.
DR N-PSDB; AAF92070.
XX
PT Eighty four nucleic acids encoding PRO polypeptides, useful in
PT molecular biology, including use as hybridization probes, and in
PT chromosome and gene mapping. -
XX
PS Claim 12; Fig 26; 278pp; English.
XX
CC The present sequence is a human PRO polypeptide (secreted and
CC transmembrane). The PRO protein, and PRO agonists, PRO antagonists or
CC anti-PRO antibodies are useful for preparation of a medicament useful in
CC the treatment of a condition which is responsive to the PRO protein,
CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be
CC employed as molecular weight markers for protein electrophoresis. The PRO
CC coding sequence has applications in molecular biology, including use as
CC hybridisation probes, and in chromosome and gene mapping.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

```
RESULT 8
AAB65191
ID   AAB65191 standard; Protein; 119 AA.
XX
AC   AAB65191;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO842 (UNQ473) protein sequence SEQ ID NO:165.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic;
KW   cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US08439.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   07-JUL-1999;   99US-0143048.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   17-AUG-1999;   99US-0149396.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   08-OCT-1999;   99US-0158663.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
XX
```

PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2001-032160/04.
DR N-PSDB; AAF44147.
XX
PT PRO polynucleotides used to produce polypeptides used to target
PT bioactive molecules such as toxins, radiolabels or antibodies, to
PT specific cells, to cause targeted cell death -
XX
PS Claim 12; Fig 99; 935pp; English.
XX
CC The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC can be used for targeted delivery of bioactive molecules, such as
CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC sequences, and their fragments, can be used as hybridisation probes, in
CC chromosomal and gene mapping, and in the generation of anti-sense RNA
CC and DNA. They may also be used to produce transgenic animals which are
CC used to develop and screen therapeutically useful reagents. The PRO
CC nucleotide and protein sequence can be used for tissue typing and in
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 9
ABP54931
ID ABP54931 standard; Protein; 119 AA.
XX
AC ABP54931;
XX
DT 08-JAN-2003 (first entry)
XX
DE Human cytokine PRO842 (CK27).
XX

KW PRO842; CK27; chemokine; human; antiinflammatory; dermatological;
KW hepatotropic; antiallergic; antiasthmatic; immunosuppressive;
KW antithyroid; antidiabetic; antianaemic; haemostatic; antipsoriatic;
KW antirheumatic; antiarthritic; nephrotropic.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..22
FT /label= Signal_peptide
FT Protein 23..119
FT /label= Mature_protein
FT Modified-site 27..32
FT /note= "potential N-myristoylation site"
FT Modified-site 39..41
FT /note= "potential protein kinase C phosphorylation
FT site"
FT Modified-site 46..51
FT /note= "potential N-myristoylation site"
XX
PN WO200270706-A2.
XX
PD 12-SEP-2002.
XX
PF 07-DEC-2001; 2001WO-US48060.
XX
PR 28-FEB-2001; 2001WO-US06520.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI French D, Grimaldi JC, Hilian KJ, Pisabarro MT, Schmidt KN;
PI Smith V, Tumas D, Vandlen RL, Watanabe CK, Williams PM, Wood WI;
XX
DR WPI; 2002-750461/81.
DR N-PSDB; ABV73914.
XX
PT New PRO842 polypeptides having structural homology to interleukin-8,
PT useful for treating or diagnosing a mammal with an inflammatory disease
PT or immune related disease, e.g. rheumatoid arthritis, osteoarthritis or
PT allergic disease -
XX
PS Claim 1; Fig 2; 118pp; English.
XX
CC The present sequence is the protein sequence of PRO842 (CK27),
CC a novel human chemokine (mol.wt. 13.8 kDa, pI 11.16) having
CC structural homology to interleukin-8. Microarray analysis has
CC shown PRO842 to be over-expressed in colon tumour, lung tumour and
CC breast tumour cells compared with non-cancerous human tissue,
CC making it a useful diagnostic marker for cancerous tumours and a
CC therapeutic target. PRO842 also plays a role in the inflammatory
CC response, having chemoattractant properties toward monocytes and
CC dendritic cells. The invention provides PRO842 polypeptides,
CC polynucleotides, host cells, vectors and antibodies, as well as
CC methods of treating an immune related disorder by using a PRO842
CC polypeptide, or an agonist, antagonist or antibody. The immune
CC related disorder may be systemic lupus erythematosus, rheumatoid

CC arthritis, osteoarthritis, juvenile chronic arthritis,
CC spondyloarthropathy, systemic sclerosis, idiopathic inflammatory
CC myopathy, Sjogren's syndrome, systemic vasculitis, sarcoidosis,
CC autoimmune haemolytic anaemia, autoimmune thrombocytopaenia,
CC thyroiditis, diabetes mellitus, immune-mediated renal disease,
CC demyelinating disease of the central or peripheral nervous system,
CC idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome,
CC chronic inflammatory demyelinating polyneuropathy, hepatobiliary
CC disease, infectious or autoimmune chronic active hepatitis, primary
CC biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis,
CC inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's
CC disease, an autoimmune or immune-mediated skin disease, a bullous
CC skin disease, erythema multiforme, contact dermatitis, psoriasis,
CC an allergic disease, asthma, allergic rhinitis, atopic dermatitis,
CC food hypersensitivity, urticaria, an immunologic disease of the
CC ovaries, an immunologic disease of the lung, eosinophilic
CC pneumonia, idiopathic pulmonary fibrosis, hypersensitivity
CC pneumonitis, a transplantation associated disease, graft rejection
CC or graft-versus-host-disease (all claimed).
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 23; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 10
ABG95863
ID ABG95863 standard; Protein; 119 AA.
XX
AC ABG95863;
XX
DT 10-DEC-2002 (first entry)
XX
DE Human secreted/transmembrane protein PRO842.
XX
KW Human; secreted protein; transmembrane protein; antirheumatic;
KW antiarthritic; osteopathic; sports-related joint problem;
KW articular cartilage defect; osteoarthritis; rheumatoid arthritis.
XX
OS Homo sapiens.
XX
PN US2002119130-A1.
XX
PD 29-AUG-2002.
XX
PF 06-DEC-2001; 2001US-0006867.
XX

PR 29-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-064215P.
PR 22-APR-1998; 98US-082797P.
PR 29-APR-1998; 98US-083495P.
PR 15-MAY-1998; 98US-085579P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 11-JUN-1998; 98US-088863P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089514P.
PR 16-SEP-1998; 98WO-US19330.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21194.
PR 22-DEC-1999; 99WO-US30720.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32378.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2002-731348/79.
DR N-PSDB; ABS74390.
XX
PT New isolated secreted and transmembrane PRO polypeptide useful for
PT modulating biological activity of a cell, or for treating
PT sports-related joint problems, osteoarthritis or rheumatoid arthritis
XX
PS Claim 20; Fig 26; 399pp; English.
XX
CC The invention relates to an isolated secreted and transmembrane PRO
CC polypeptide having 80 % sequence identity to a sequence appearing
CC as ABG95851-ABG95934 or their associated signal peptide, or a sequence of
CC an extracellular domain of the proteins with their associated signal
CC peptide or lacking its associated signal peptide. Also included are
CC the nucleic acids encoding the proteins, vectors, host cells,
CC fusion proteins and antibodies which specifically bind to the proteins.
CC The proteins are useful for detecting a polypeptide designated as A, B, C
CC or D in a sample suspected of containing an A, B, C or D polypeptide,

CC by contacting the sample with a polypeptide designated as E, F, G, H or
CC I (or vice versa) and determining the formation of a A/E, B/F, B/G, C/H
CC or D/I polypeptide conjugate in the sample, where the formation of the
CC conjugate is indicative of the presence of an A, B, C or D polypeptide
CC in the sample, where A is a PRO10272 polypeptide, B is a PRO20110
CC polypeptide, C is a PRO10096 polypeptide, D is a PRO19760 polypeptide,
CC E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040
CC polypeptide, H is a PRO20233 polypeptide and I is a PRO1890
CC polypeptide. The sample comprises a cell suspected of expressing the A,
CC B, C or D polypeptide. The E, F, G, H or I polypeptide is labeled with
CC a detectable label or is attached to a solid support. The proteins are
CC useful for linking a bioactive molecule to a cell expressing a
CC polypeptide designated as A, B, C or D or E, F, G, H or I. The bioactive
CC molecule is a toxin, a radiolabel or an antibody. The bioactive molecule
CC causes death of the cell. A, B, C, D, E, F, G, H, or I, or antibodies
CC against them are useful for modulating a biological activity of a cell
CC expressing a polypeptide designated as A, B, C or D or E, F, G, H, or
CC I. The cell is killed. The proteins are useful for identifying
CC agonists or antagonists, for the preparation of a medicament useful in
CC the treatment of a condition which is responsive to the proteins, as
CC molecular weight markers for protein electrophoresis purposes, and as
CC therapeutic agents for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis or rheumatoid arthritis.
CC Nucleic acids encoding the proteins are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of anti-sense RNA and
CC DNA, for the preparation of the proteins, to generate transgenic or
CC knockout animals which are useful in the development and screening of
CC therapeutic useful reagents, for chromosome identification, and in gene
CC therapy. The antibody is useful as a therapeutic agent, in a diagnostic
CC assay and for affinity purification of the protein from recombinant
CC cell culture natural sources. The present sequence represents a novel
CC secreted or transmembrane protein of the invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 23; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 11
ABU71181
ID ABU71181 standard; Protein; 119 AA.
XX
AC ABU71181;
XX
DT 10-JUN-2003 (first entry)
XX
DE Human PRO842 protein.

XX
KW Human; PRO; secreted; transmembrane; cytostatic; TNF-alpha; blood;
KW tumour necrosis factor alpha release; chondrocyte cell; proliferation;
KW differentiation; tumour; gene therapy.
XX
OS Homo sapiens.
XX
PN US2003036143-A1.
XX
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-0187600.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.

PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.

PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.
PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.

PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.
PR 10-SEP-1998; 98US-099754P.
PR 10-SEP-1998; 98US-099763P.
PR 10-SEP-1998; 98US-099812P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 12
ABU71518
ID ABU71518 standard; Protein; 119 AA.
XX
AC ABU71518;
XX
DT 10-JUN-2003 (first entry)
XX
DE Human secreted polypeptide PRO842.
XX
KW Human; gene therapy; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003013855-A1.
XX
PD 16-JAN-2003.
XX
PF 03-MAY-2002; 2002US-0063616.
XX
PR 30-DEC-1998; 98KR-0062142.

PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 30-DEC-1999; 99WO-US31274.
PR 18-FEB-2000; 2000WO-US04341.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 21-MAR-2000; 2000WO-US07532.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 24-AUG-2000; 2000WO-US23328.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 14-MAY-1999; 99US-0311832.
PR 25-AUG-1999; 99US-0380137.
PR 25-AUG-1999; 99US-0380138.
PR 25-AUG-1999; 99US-0380139.
PR 25-AUG-1999; 99US-0380142.
PR 15-SEP-1999; 99US-0397342.
PR 18-OCT-1999; 99US-0403297.
PR 12-NOV-1999; 99US-0423844.
PR 22-AUG-2000; 2000US-0644848.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 08-NOV-2000; 2000US-0709238.
PR 20-DEC-2000; 2000US-0747259.
PR 22-MAR-2001; 2001US-0816744.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 30-MAY-2001; 2001US-0870574.
PR 05-JUN-2001; 2001US-0874503.
PR 29-JUN-2001; 2001US-0869599.
PR 18-JUL-2001; 2001US-0908827.
PR 06-DEC-2001; 2001US-0006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-330485/31.
DR N-PSDB; ACA58822.
XX
PT New isolated antibody specifically binding a PRO polypeptide, useful
PT for the preparation of a medicament for treating disorders with the
PT aberrant expression or activity of the PRO polypeptide, such as tumor
PT conditions and cancer -
XX
PS Disclosure; Page 93; 406pp; English.
XX
CC The invention relates to an antibody that binds to a polypeptide with a
CC fully defined sequence given in the specification. The methods and
CC compositions (containing antibodies that specifically bind a PRO
CC polypeptide) of the present invention are useful for the preparation of a
CC medicament for the treatment of disorders associated with the aberrant

CC expression or activity of the PRO polypeptide, such as tumour conditions
CC and cancer. They can also be used to generate transgenic or knockout
CC animals useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides and encoding nucleic acids can be used as
CC molecular weight markers for protein electrophoresis, chromosome
CC identification and tissue typing. The PRO polypeptides are useful to
CC induce angiogenesis e.g wound healing; in the treatment of sports-related
CC joint problems, articular cartilage defects, osteoarthritis or rheumatoid
CC arthritis; diabetes; hyperinsulinaemia and hypoinsulinaemia. The
CC antibodies may be used in various diagnostic, competitive binding and/or
CC immunoprecipitation assays. The present sequence represents the amino
CC acid sequence of a PRO polypeptide of the invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 13
ABU71964
ID ABU71964 standard; Protein; 119 AA.
XX
AC ABU71964;
XX
DT 11-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO842.
XX
KW Human; secreted and transmembrane polypeptide;
KW chromosome mapping; gene mapping; transgenic animal; knockout animal;
KW therapeutic agent screening; chromosome identification; tissue typing;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003018183-A1.
XX
PD 23-JAN-2003.
XX
PF 01-MAY-2002; 2002US-0063512.
XX
PR 06-DEC-2001; 2001US-0006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX
DR WPI; 2003-330984/31.
DR N-PSDB; ACA60375.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules encoding the polypeptides, useful in gene therapy or
PT preparing a medicament for treating a condition that is responsive to
PT the PRO polypeptide or antibody -
XX
PS Disclosure; Fig 26; 409pp; English.
XX
CC The invention describes novel isolated PRO polypeptides. The PRO
CC polypeptides or anti-PRO antibodies are useful in preparing a medicament
CC for treating a condition that is responsive to the PRO polypeptide or
CC antibody. The PRO nucleotide sequences may be used as hybridisation
CC probes in chromosome and gene mapping, or in generating antisense RNA
CC and DNA. PRO nucleic acids are also useful in preparing PRO polypeptides,
CC in assays to identify other proteins or molecules involved in binding
CC reaction, to generate transgenic animals or knockout animals, which in
CC turn are useful in the development and screening of therapeutically
CC useful reagents, for chromosome identification, and tissue typing. The
CC PRO polypeptides and nucleic acid molecules are also useful in gene
CC therapy, and as molecular weight markers for protein electrophoresis
CC purposes. The anti-PRO antibodies may be used in diagnostic assays for
CC PRO, or for the affinity purification of PRO from recombinant cell
CC culture or natural sources. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO poypeptide.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 14
ABU72121
ID ABU72121 standard; Protein; 119 AA.
XX
AC ABU72121;
XX
DT 13-JUN-2003 (first entry)
XX
DE Human PRO polypeptide #13.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression.
XX
OS Homo sapiens.

XX
PN US2003023042-A1.
XX
PD 30-JAN-2003.
XX
PF 01-MAY-2002; 2002US-0063502.
XX
PR 06-DEC-2001; 2001US-0006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-331484/31.
DR N-PSDB; ACA63385.
XX
PT Novel monoclonal antibody that binds to secreted and transmembrane
PT polypeptide, useful for detecting and purifying the polypeptide and
PT also for treating conditions responsive to the antibody -
XX
PS Disclosure; Fig 26; 408pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a
CC medicament useful in the treatment of a condition responsive to
CC anti-PRO antibody. Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells,
CC tissues or serum, and for affinity purification of PRO from
CC recombinant cell culture or natural sources. ABU72109-ABU72192
CC represent the human PRO polypeptides of the invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 15
ABU65638
ID ABU65638 standard; Protein; 119 AA.
XX
AC ABU65638;
XX
DT 19-MAY-2003 (first entry)
XX

DE Human secreted/transmembrane protein, SEQ ID 140.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW cytostatic; antiarthritic; osteopathic; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; TNF-alpha release; arthritis;
KW tumour necrosis factor alpha; chondrocyte cell; bone disorder;
KW cartilage disorder; sports injury.
XX
OS Homo sapiens.
XX
PN US2003036156-A1.
XX
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-0188767.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.

PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.

PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.

PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 16
ABU65971
ID ABU65971 standard; Protein; 119 AA.
XX
AC ABU65971;
XX
DT 20-MAY-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO842.
XX
KW Human; secreted protein; transmembrane protein; cytostatic;
KW gene Therapy; TNF-Agonist-Alpha; chondrocyte stimulator; tumour;
KW adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036157-A1.
XX
PD 20-FEB-2003.

XX
PF 02-JUL-2002; 2002US-0188769.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.

PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.

PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.
PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.

PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.
PR 10-SEP-1998; 98US-099754P.
PR 10-SEP-1998; 98US-099763P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 17
ABU67475
ID ABU67475 standard; Protein; 119 AA.
XX
AC ABU67475;
XX
DT 29-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) #70.
XX
KW Human; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing.
XX
OS Homo sapiens.
XX
PN US2003036162-A1.
XX
PD 20-FEB-2003.
XX
PF 12-JUL-2002; 2002US-0194423.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.

PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 26-JUN-1998; 98US-0105413.
PR 07-OCT-1998; 98US-0168978.
PR 06-NOV-1998; 98US-0187368.
PR 07-DEC-1998; 98US-0202054.
PR 03-MAR-1999; 99US-0254311.
PR 14-MAY-1999; 99US-0311832.
PR 14-MAY-1999; 99US-0380137.
PR 25-AUG-1999; 99US-0380138.
PR 25-AUG-1999; 99US-0380139.
PR 25-AUG-1999; 99US-0380142.
PR 18-OCT-1999; 99US-0403297.
PR 12-NOV-1999; 99US-0423844.
PR 22-AUG-2000; 2000US-0644848.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 08-NOV-2000; 2000US-0709238.
PR 20-DEC-2000; 2000US-0747259.
PR 22-MAR-2001; 2001US-0816744.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 05-JUN-2001; 2001US-0874503.
PR 18-JUL-2001; 2001US-0908827.
PR 30-JUL-2001; 2001US-0918585.
PR 06-AUG-2001; 2001US-0924419.
PR 13-AUG-2001; 2001US-0929404.
PR 16-AUG-2001; 2001US-0931836.
PR 28-AUG-2001; 2001US-0941992.
PR 04-SEP-2001; 2001US-0946374.
PR 15-JAN-2002; 2002US-0052586.
XX
PA (GETH) GENENTECH INC.

XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332039/31.
DR N-PSDB; ACA05769.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids,
PT useful in gene therapy, in chromosome and gene mapping, as chromosome
PT markers, in tissue typing, and in chromosome identification -
XX
PS Claim 11; Fig 140; 706pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides. Also disclosed is an antibody that
CC specifically binds to the PRO polypeptide, a method for stimulating the
CC release of tumour necrosis factor alpha (TNF-alpha) from human blood by
CC contacting the blood a PRO polypeptide, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells by contacting the
CC cells with a PRO polypeptide, a method for detecting the presence of a
CC tumour in a mammal and an oligonucleotide probe derived from any of the
CC PRO nucleotide sequences. The nucleotide sequences are useful as probes,
CC in chromosome and gene mapping, in generating antisense RNA and DNA, in
CC preparing PRO polypeptides by recombinant techniques and in gene therapy
CC (e.g. for replacement of defective gene). The PRO polypeptides are useful
CC as molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence of a tumour. The PRO polypeptides and nucleic
CC acids may also be used diagnostically for tissue typing. The sequences
CC presented in ABU67406-ABU67710 are the PRO polypeptides of the invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 18
ABU65333
ID ABU65333 standard; Protein; 119 AA.
XX
AC ABU65333;
XX
DT 16-MAY-2003 (first entry)
XX
DE Human PRO polypeptide #70.

XX
KW Human; PRO; cytostatic; chromosome mapping; gene mapping;
KW protein electrophoresis; tumour necrosis factor-alpha; TNF-alpha; blood;
KW chondrocyte differentiation; chondrocyte proliferation; tumour.
XX
OS Homo sapiens.
XX
PN US2003032102-A1.
XX
PD 13-FEB-2003.
XX
PF 17-JUN-2002; 2002US-0173697.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.

PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.

PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.
PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.

PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.
PR 10-SEP-1998; 98US-099754P.
PR 10-SEP-1998; 98US-099763P.
PR 10-SEP-1998; 98US-099812P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy      61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 19
ABU59084
ID ABU59084 standard; Protein; 119 AA.
XX
AC ABU59084;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO842.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX

OS Homo sapiens.
XX
PN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-0990442.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-247083/24.
DR N-PSDB; ABX80231.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346

PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments -
XX
PS Claim 12; Fig 99; 648pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and
CC are thus useful for treating sports injuries, and arthritis. This
CC is the amino acid sequence of a novel human PRO protein.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 20
ABU59231
ID ABU59231 standard; Protein; 119 AA.
XX
AC ABU59231;
XX

DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #61.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic;
KW gene therapy; tumour-associated antigenic target; TAT; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997428.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.

PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.

PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.

PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 21
ABU59380
ID ABU59380 standard; Protein; 119 AA.
XX
AC ABU59380;
XX
DT 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO839.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;

KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003027985-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-0990562.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.

PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.

PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.

PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 22
ABU60515
ID ABU60515 standard; Protein; 119 AA.
XX
AC ABU60515;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #61.
XX
KW Human; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; therapeutic; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002160384-A1.
XX
PD 31-OCT-2002.
XX
PF 14-NOV-2001; 2001US-0992598.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.

PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-288106/28.
DR N-PSDB; ABX90209.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes -
XX
PS Claim 12; Fig 99; 650pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein
CC electrophoresis, and the isolated nucleic acids may be used for
CC recombinantly expressing those markers. The PRO polypeptides and nucleic
CC acids may also be used in tissue typing. Anti-PRO antibodies are useful

CC in diagnostic assays for PRO, and in affinity purification of PRO from
CC recombinant cell culture or natural sources. The sequences presented in
CC ABU60478-ABU60624 are the PRO polynucleotides of the invention.
CC Note: The sequence data for this patent is also available in electronic
CC format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 23
ABU58006
ID ABU58006 standard; Protein; 119 AA.
XX
AC ABU58006;
XX
DT 14-APR-2003 (first entry)
XX
DE Human PRO polypeptide #38.
XX
KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
KW horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy.
XX
OS Homo sapiens.
XX
PN US2003027163-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997666.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.

PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.

PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.
PR 07-JUL-1999; 99US-143048P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

```
RESULT 24
ABU58469
ID   ABU58469 standard; Protein; 119 AA.
XX
AC   ABU58469;
XX
DT   15-APR-2003  (first entry)
XX
DE   Human PRO polypeptide #70.
XX
KW   Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach;
KW   liver; dog; cat; cow; horse; sheep; pig; goat; rabbit; ADEPT;
KW   antibody-dependent enzyme mediated prodrug therapy.
XX
OS   Homo sapiens.
XX
PN   US2003027272-A1.
XX
PD   06-FEB-2003.
XX
PF   21-JUN-2002; 2002US-0176492.
XX
PR   16-SEP-1998;   98WO-US19330.
PR   07-OCT-1998;   98WO-US21141.
PR   01-DEC-1998;   98WO-US25108.
PR   08-MAR-1999;   99WO-US05028.
PR   10-MAR-1999;   99WO-US05190.
PR   14-MAY-1999;   99WO-US10733.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   15-SEP-1999;   99WO-US21090.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28551.
PR   30-DEC-1999;   99WO-US31274.
PR   05-JAN-2000; 2000WO-US00219.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   10-MAR-2000; 2000WO-US06319.
PR   15-MAR-2000; 2000WO-US06884.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
```

PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.

PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.

PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.
PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 25
ABU58937
ID ABU58937 standard; Protein; 119 AA.

XX
AC ABU58937;
XX
DT 16-APR-2003 (first entry)
XX
DE Human sectreted/transmembrane protein, #61.
XX
KW Human; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;
KW colon cancer; lung cancer; breast cancer;cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PF 19-NOV-2001; 2001US-0989721.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.

PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-155950/15.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers
PT -
XX
PS Claim 12; Fig 99; 647pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABU58900-ABU59046 are the PRO polypeptides of the invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 26
ABU56005
ID ABU56005 standard; Protein; 119 AA.
XX
AC ABU56005;
XX
DT 26-MAR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, PRO842.

XX
KW Human; secreted protein; transmembrane protein; PRO;
KW antiarthritic; vulnerary; tumour necrosis factor-alpha;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW tumour; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour;
KW bone disorder; cartilage disorder; arthritis; sports injury.
XX
OS Homo sapiens.
XX
PN US2003022298-A1.
XX
PD 30-JAN-2003.
XX
PF 20-JUN-2002; 2002US-0176913.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 20-NOV-1998; 98WO-US24855.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99WO-US05190.
PR 20-APR-1999; 99WO-US08615.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 22-MAR-2001; 2001WO-US09552.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.

PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.

PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 27
ABU57000
ID ABU57000 standard; Protein; 119 AA.
XX
AC ABU57000;
XX
DT 04-APR-2003 (first entry)
XX
DE Human PRO polypeptide #70.
XX
KW Human; PRO; tumour necrosis factor-alpha; blood; cancer;
KW chondrocyte cell; tumour; adrenal tumour; lung; colon; breast; prostate;
KW kidney; rectum; cervix; liver; bone disorder; cartilage disorder;
KW arthritis; sports injury; genetic disorder; antiarthritic; vulnerary.
XX
OS Homo sapiens.
XX
PN US2003027280-A1.
XX
PD 06-FEB-2003.
XX

PF 20-JUN-2002; 2002US-0176993.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.

PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088722P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088740P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.

PR 10-JUN-1998; 98US-088825P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088863P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089090P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090461P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090688P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 26-JUN-1998; 98US-091010P.
PR 01-JUL-1998; 98US-091359P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091486P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091632P.
PR 24-JUL-1998; 98US-094006P.
PR 04-AUG-1998; 98US-095282P.
PR 10-AUG-1998; 98US-095998P.
PR 10-AUG-1998; 98US-096012P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-097022P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.

PR 26-AUG-1998; 98US-098014P.
PR 01-SEP-1998; 98US-098716P.
PR 01-SEP-1998; 98US-098723P.
PR 02-SEP-1998; 98US-098803P.
PR 02-SEP-1998; 98US-098821P.
PR 02-SEP-1998; 98US-098843P.
PR 09-SEP-1998; 98US-099602P.
PR 10-SEP-1998; 98US-099741P.
PR 10-SEP-1998; 98US-099754P.
PR 10-SEP-1998; 98US-099763P.

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 28
ABU13897
ID ABU13897 standard; Protein; 119 AA.
XX
AC ABU13897;
XX
DT 26-FEB-2003 (first entry)
XX
DE Human PRO842 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-0989731.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.

PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH LTD.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-102117/09.
DR N-PSDB; ABX64055.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers -
XX
PS Claim 12; Fig 99; 649pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for for identifying agonists or antagonists.
CC The polynucleotide sequences encoding PRO polypeptides are useful as
CC hybridisation probes, in chromosome and gene mapping, in the generation
CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
CC generating transgenic animals or knockout animals, to construct
CC hybridisation probes for mapping the gene which encodes the PRO
CC polypeptide, and for the genetic analysis of individuals with genetic
CC disorders, in gene therapy, for chromosome identification, as
CC chromosome markers, and for generating probes for PCR, Northern

CC analysis, Southern analysis and Western analysis. ABU13860-ABU14006
CC represent the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 29
ABU10579
ID ABU10579 standard; Protein; 119 AA.
XX
AC ABU10579;
XX
DT 03-FEB-2003 (first entry)
XX
DE Human secreted/transmembrane protein #70.
XX
KW Human; secreted and transmembrane protein; blood;
KW tumour necrosis factor-alpha; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; bone disorder; cartilage disorder;
KW arthritis; sports injury.
XX
OS Homo sapiens.
XX
PN US2002127584-A1.
XX
PD 12-SEP-2002.
XX
PF 15-JAN-2002; 2002US-0052586.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 06-JAN-1999; 2000WO-US00219.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28551.

PR 30-DEC-1999; 99WO-US31274.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 29-AUG-2001; 2001WO-US27099.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077649P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.

PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-066893/06.
DR N-PSDB; ABX16655.
XX
PT Novel isolated PRO polypeptides e.g., PRO1079, PRO827, PRO791, PRO1131,
PT PRO1316, PRO1183, PRO1343, PRO1760, PRO1567 or PRO4333, useful for
PT stimulating release of tumor necrosis factor-alpha from human blood -
XX
PS Claim 11; Fig 140; 701pp; English.
XX
CC The invention relates to an isolated PRO polypeptide comprising at least
CC 80% sequence identity to the protein sequences appearing as ABU10510-
CC ABU10814 (including a version lacking its associated signal peptide, or
CC an isolated extracellular domain of a PRO polypeptide with or without
CC its associated signal peptide. Also included are the nucleic acids
CC encoding the PRO proteins (being secreted and transmembrane proteins)
CC appearing as ABX16586-ABX16590, PRO expression vectors, host cells,
CC chimaeric PRO fusion proteins, an anti-PRO antibody and a PRO
CC derived oligonucleotide sequence. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha from human blood.
CC The PRO polypeptide PRO6029 is useful for stimulating proliferation or
CC differentiation of chondrocyte cells. The PRO polypeptides as specified
CC in the specification and having differential expression in tumour cells,
CC are useful for detecting presence of tumour in a mammal (such as adrenal
CC tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal
CC tumour, cervical tumour or liver tumour. The PRO polypeptide PRO6029 is
CC useful for treating various bone and/or cartilage disorders such as
CC arthritis, and sports injuries. The PRO polypeptides are useful for
CC screening compounds to identify ant/agonists. PRO nucleic acids
CC are useful as hybridisation probes, in chromosome and gene mapping,
CC in the generation of anti-sense RNA and DNA, for the preparation of PRO
CC polypeptides and for generating knock-out animals. The present
CC sequence represents a PRO polypeptide.
XX
SQ Sequence 119 AA;

```
  Query Match             100.0%;  Score 644;  DB 24;  Length 119;
  Best Local Similarity   100.0%;  Pred. No. 1.8e-66;
  Matches  119;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119


RESULT 30
ABU10852
ID   ABU10852 standard; Protein; 119 AA.
XX
AC   ABU10852;
XX
DT   04-FEB-2003  (first entry)
XX
DE   Human PRO polypeptide #38.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   toxin; radiolabel; cell death; gene mapping; chromosome mapping;
KW   protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW   antibacterial.
XX
OS   Homo sapiens.
XX
PN   US2002123463-A1.
XX
PD   05-SEP-2002.
XX
PF   19-NOV-2001; 2001US-0989732.
XX
PR   05-NOV-1997;   97WO-US20069.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   02-JUN-1999;   99WO-US12252.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   06-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
```

PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.

PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-066810/06.
DR N-PSDB; ABX17019.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers -
XX
PS Claim 12; Fig 99; 655pp; English.
XX
CC The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying
CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention.
XX
SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.8e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
```

RESULT 31
AAY82454
ID AAY82454 standard; Protein; 97 AA.
XX
AC AAY82454;
XX
DT 30-JUN-2000 (first entry)
XX
DE Mature human TGC-440 secretory protein SEQ ID NO:7.
XX
KW TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
XX
OS Homo sapiens.
XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PF 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
DR N-PSDB; AAA08345.
XX
PT Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX
PS Disclosure; Page 80; 86pp; Japanese.
XX
CC The present sequence represents the mature human secretory protein
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence

CC encoding it can be used to treat, prevent and diagnose immunological,
CC lung, liver, kidney or gastrointestinal disorders and infectious
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX
SQ Sequence 97 AA;

Query Match 85.1%; Score 548; DB 21; Length 97;
Best Local Similarity 100.0%; Pred. No. 1.8e-55;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         23 SLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKG 82
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 SLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKG 60

Qy         83 NVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||||||
Db         61 NVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 97
```

RESULT 32
AAW83953
ID AAW83953 standard; Protein; 93 AA.
XX
AC AAW83953;
XX
DT 28-JAN-1999 (first entry)
XX
DE Polypeptide encoded by gene 7 clone HJPDJ64.
XX
KW Secreted protein; gene therapy; protein therapy; diagnosis; treatment;
KW central nervous system; CNS; immune system; cancer; trauma; liver;
KW reproductive disorder; congenital malformation; degenerative disease;
KW inflammatory disease; neoplasia; metabolic disorder; testis; placenta;
KW brain; T cell; spleen; lung; heart; rhabdomyosarcoma; endocrine system;
KW endocrinopathy; endocrine polyglandular syndrome; endocrinoma; sepsis;
KW endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone.
XX
OS Homo sapiens.
XX
PN WO9845712-A2.
XX
PD 15-OCT-1998.
XX
PF 07-APR-1998; 98WO-US06801.
XX
PR 30-MAY-1997; 97US-0048184.
PR 08-APR-1997; 97US-0042726.
PR 08-APR-1997; 97US-0042727.
PR 08-APR-1997; 97US-0042728.
PR 08-APR-1997; 97US-0042754.
PR 08-APR-1997; 97US-0042825.
PR 30-MAY-1997; 97US-0048068.
PR 30-MAY-1997; 97US-0048070.

XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Feng P, Ni J, Rosen CA, Ruben SM, Yu G;
XX
DR WPI; 1998-594496/50.
XX
PT New isolated human genes and secreted polypeptide(s) they encode -
PT useful for the diagnosis and treatment of e.g. cancers, CNS
PT disorders, immune system disorders, inflammatory disease and
PT bacterial infections
XX
PS Disclosure; Page 10; 142pp; English.
XX
CC This represents a polypeptide encoded by the nucleic acid molecule
CC designated Gene 7 from the human cDNA clone HJPDJ64 (deposited
CC as clone ATCC 97955 and ATCC 209074) which encodes a human secreted
CC protein of the invention. The gene is expressed primarily in liver,
CC spleen, bone marrow and to a lesser extent in amygdala and is useful as
CC reagents for differential identification of tissues in a biological
CC sample.
CC The invention relates to 20 novel genes and their fragments (AAV69611 to
CC AAV69630) and corresponding secreted proteins (AAW83931 to AAW83950)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein of gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the
CC polynucleotides. Specific uses are based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of central nervous system (CNS) and immune system diseases,
CC reproductive disorders, cancers, congenital malformations, degenerative
CC diseases, trauma, inflammatory disease, neoplasia, metabolic disorders,
CC diseases in testes, placenta, liver, brain and activated T cells, spleen
CC diseases, lung diseases, heart diseases, rhabdomyosarcoma and disorders
CC of the endocrine system or other endocrinopathies, e.g. endocrine
CC polyglandular syndrome, endocrinoma, and endocrine ophthalmopathy,
CC osteoclastoma and other bone remodelling disorders, bacterial infections
CC and sepsis. The polypeptides are also useful for identifying their
CC binding partners.
XX
SQ Sequence 93 AA;

Query Match 81.8%; Score 527; DB 19; Length 93;
Best Local Similarity 100.0%; Pred. No. 4.5e-53;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         27 GVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKGNVKK 86
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKGNVKK 60

Qy         87 TRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              |||||||||||||||||||||||||||||||||
Db         61 TRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 93
```

RESULT 33
AAY82457

ID AAY82457 standard; Protein; 119 AA.
XX
AC AAY82457;
XX
DT 30-JUN-2000 (first entry)
XX
DE Mouse TGC-440 secretory protein SEQ ID NO:3.
XX
KW TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
XX
OS Mus sp.
XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PF 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
DR N-PSDB; AAA08349, AAA08350.
XX
PT Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX
PS Claim 1; Fig 3; 86pp; Japanese.
XX
CC The present sequence represents a mouse secretory protein designated
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC encoding it can be used to treat, prevent and diagnose immunological,
CC lung, liver, kidney or gastrointestinal disorders and infectious
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX
SQ Sequence 119 AA;

  Query Match   70.8%; Score 456; DB 21; Length 119;
  Best Local Similarity   71.4%; Pred. No. 9.6e-45;
  Matches   85; Conservative   9; Mismatches   25; Indels   0; Gaps   0;

Qy   1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

```
                ||:| |  |||||:|||||| || |||||| | |:  | |||| |||||||||||||:||
Db          1 MKLLASPFLLLLPVMLMSMVFSSPNPGVARSHGDQHLAPRRWLLEGGQECECKDWFLQAP 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
               :||   | | |:||||||| ||  || |||:|||| : |||||||||:| | ||||||
Db         61 KRKATAVLGPPRKQCPCDHVKGREKKNRHQKHHRKSQRPSRACQQFLKRCHLASFALPL 119


RESULT 34
AAY82458
ID   AAY82458 standard; Protein; 97 AA.
XX
AC   AAY82458;
XX
DT   30-JUN-2000  (first entry)
XX
DE   Mature mouse TGC-440 secretory protein SEQ ID NO:9.
XX
KW   TGC-440; secretory protein; immunological disease; infectious disease;
KW   pulmonary function disorder; hepatic function disorder; nephrotropic;
KW   gastrointestinal function disorder; antiinflammatory; immunomodulatory;
KW   virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW   hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW   pneumonia; Helicobacter pylori infection.
XX
OS   Mus sp.
XX
PN   WO200014226-A1.
XX
PD   16-MAR-2000.
XX
PF   02-SEP-1999;   99WO-JP04765.
XX
PR   03-SEP-1998;   98JP-0250108.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Itoh Y,  Ogi K,  Tanaka H,  Kitada C;
XX
DR   WPI; 2000-256978/22.
DR   N-PSDB; AAA08351.
XX
PT   Secretory protein TGC440, antibodies to it and compounds promoting or
PT   inhibiting its activity for diagnosis and treatment of diseases of the
PT   immune system, lung, kidney, liver and intestinal system  -
XX
PS   Disclosure; Page 81-82; 86pp; Japanese.
XX
CC   The present sequence represents the mature mouse secretory protein
CC   TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC   virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC   and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC   encoding it can be used to treat, prevent and diagnose immunological,
CC   lung, liver, kidney or gastrointestinal disorders and infectious
CC   diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC   pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC   immunospecific for TGC-440 is also useful in the above treatment and
```

CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX
SQ Sequence 97 AA;

Query Match 59.9%; Score 386; DB 21; Length 97;
Best Local Similarity 71.1%; Pred. No. 9.2e-37;
Matches 69; Conservative 7; Mismatches 21; Indels 0; Gaps 0;

```
Qy         23 SLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKG 82
              | |||||| | |:  | |||| |||||||||||||:||:||   | | |:||||||| ||
Db          1 SPNPGVARSHGDQHLAPRRWLLEGGQECECKDWFLQAPKRKATAVLGPPRKQCPCDHVKG 60

Qy         83 NVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
                || |||:|||| : |||||||||:| | ||||||
Db         61 REKKNRHQKHHRKSQRPSRACQQFLKRCHLASFALPL 97
```

RESULT 35
AAY82455
ID AAY82455 standard; Protein; 119 AA.
XX
AC AAY82455;
XX
DT 30-JUN-2000 (first entry)
XX
DE Rat TGC-440 secretory protein SEQ ID NO:2.
XX
KW TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
XX
OS Rattus sp.
XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PF 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
DR N-PSDB; AAA08346, AAA08347.
XX
PT Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX
PS Claim 1; Fig 2; 86pp; Japanese.

```
XX
CC   The present sequence represents a rat secretory protein designated
CC   TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC   virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC   and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC   encoding it can be used to treat, prevent and diagnose immunological,
CC   lung, liver, kidney or gastrointestinal disorders and infectious
CC   diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC   pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC   immunospecific for TGC-440 is also useful in the above treatment and
CC   diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC   specimen.
XX
SQ   Sequence   119 AA;

  Query Match             59.9%;  Score 386;  DB 21;  Length 119;
  Best Local Similarity   63.0%;  Pred. No. 1.2e-36;
  Matches   75;  Conservative   10;  Mismatches   34;  Indels    0;  Gaps    0;

Qy          1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
              ||:| |  ||||  |  : |||| |  ||| | |: || |||| ||||||:|||| ||
Db          1 MKLLASPFLLLLTGMFTATVSSSPNQEVARHHGDQHQAPRRWLWEGGQECDCKDWSLRVS 60

Qy         61 RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              :||   |   |:||||||| ||: || | |:||||  : || ||||||:||| ||||||
Db         61 KRKTTAVLEPPRKQCPCDHVKGSEKKNRRQKHHRKSQRPSRTCQQFLKRCQLASFALPL 119


RESULT 36
AAY11732
ID   AAY11732 standard; Protein; 69 AA.
XX
AC   AAY11732;
XX
DT   18-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID No: 332.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906550-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB01232.
XX
PR   01-AUG-1997;   97US-0905144.
XX
PA   (GEST ) GENSET.
XX
```

PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153780/13.
DR N-PSDB; AAX40454.
XX
PT New isolated prostate-derived nucleic acids - used to develop
PT products which may have cytokine, immune regulatory, haematopoiesis
PT regulating, anti-inflammatory or tumour inhibition activity
XX
PS Claim 34; Page 512; 675pp; English.
XX
CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 69 AA;

  Query Match 55.6%; Score 358; DB 20; Length 69;
  Best Local Similarity 100.0%; Pred. No. 1.1e-33;
  Matches 69; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60
    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60

Qy 61 RRKFMTVSG 69
       |||||||||
Db 61 RRKFMTVSG 69

RESULT 37
AAY82456
ID AAY82456 standard; Protein; 97 AA.
XX
AC AAY82456;
XX
DT 30-JUN-2000 (first entry)
XX
DE Mature rat TGC-440 secretory protein SEQ ID NO:8.
XX
KW TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;

KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
XX
OS Rattus sp.
XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PF 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
DR N-PSDB; AAA08348.
XX
PT Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system -
XX
PS Disclosure; Page 81; 86pp; Japanese.
XX
CC The present sequence represents a mature rat secretory protein designated
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC encoding it can be used to treat, prevent and diagnose immunological,
CC lung, liver, kidney or gastrointestinal disorders and infectious
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.
XX
SQ Sequence 97 AA;

Query Match 53.1%; Score 342; DB 21; Length 97;
Best Local Similarity 64.9%; Pred. No. 1.1e-31;
Matches 63; Conservative 8; Mismatches 26; Indels 0; Gaps 0;

```
Qy         23 SLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAPRRKFMTVSGLPKKQCPCDHFKG 82
              | |  ||| | |: || |||| ||||||:|||| ||  :||   |   |:||||||| ||
Db          1 SPNQEVARHHGDQHQAPRRWLWEGGQECDCKDWSLRVSKRKTTAVLEPPRKQCPCDHVKG 60

Qy         83 NVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL 119
              : || | |:|||  : || ||||||:||| ||||||
Db         61 SEKKNRRQKHHRKSQRPSRTCQQFLKRCQLASFALPL 97
```

RESULT 38
AAW83938
ID AAW83938 standard; Protein; 64 AA.

XX
AC AAW83938;
XX
DT 28-JAN-1999 (first entry)
XX
DE Human secreted protein from gene 8 clone HLHCM89.
XX
KW Secreted protein; gene therapy; protein therapy; diagnosis; treatment;
KW central nervous system; CNS; immune system; cancer; trauma; liver;
KW reproductive disorder; congenital malformation; degenerative disease;
KW inflammatory disease; neoplasia; metabolic disorder; testis; placenta;
KW brain; T cell; spleen; lung; heart; rhabdomyosarcoma; endocrine system;
KW endocrinopathy; endocrine polyglandular syndrome; endocrinoma; sepsis;
KW endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..26
FT /note= "signal peptide"
FT Protein 27..64
FT /note= "mature secreted protein"
FT Misc-difference 38
FT /label= unknown
FT /note= "encoded by GST"
FT Misc-difference 51
FT /label= unknown
FT /note= "encoded by RAG"
XX
PN WO9845712-A2.
XX
PD 15-OCT-1998.
XX
PF 07-APR-1998; 98WO-US06801.
XX
PR 30-MAY-1997; 97US-0048184.
PR 08-APR-1997; 97US-0042726.
PR 08-APR-1997; 97US-0042727.
PR 08-APR-1997; 97US-0042728.
PR 08-APR-1997; 97US-0042754.
PR 08-APR-1997; 97US-0042825.
PR 30-MAY-1997; 97US-0048068.
PR 30-MAY-1997; 97US-0048070.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Feng P, Ni J, Rosen CA, Ruben SM, Yu G;
XX
DR WPI; 1998-594496/50.
DR N-PSDB; AAV69618.
XX
PT New isolated human genes and secreted polypeptide(s) they encode -
PT useful for the diagnosis and treatment of e.g. cancers, CNS
PT disorders, immune system disorders, inflammatory disease and
PT bacterial infections
XX
PS Claim 11; Page 120; 142pp; English.

XX
CC This sequence represents a human secreted protein encoded by a nucleic
CC acid molecule designated Gene 8 from the human cDNA clone HLHCM89
CC (deposited as clone ATCC 97955 and ATCC 209074). The gene is expressed
CC primarily in lung and to a lesser extent in pancreatic carcinoma and
CC gall bladder and is useful as reagents for differential identification
CC of tissues in a biological sample.
CC The invention relates to 20 novel genes and their fragments (AAV69611 to
CC AAV69630) and corresponding secreted proteins (AAW83931 to AAW83950)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein of gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the
CC polynucleotides. Specific uses are based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of central nervous system (CNS) and immune system diseases,
CC reproductive disorders, cancers, congenital malformations, degenerative
CC diseases, trauma, inflammatory disease, neoplasia, metabolic disorders,
CC diseases in testes, placenta, liver, brain and activated T cells, spleen
CC diseases, lung diseases, heart diseases, rhabdomyosarcoma and disorders
CC of the endocrine system or other endocrinopathies, e.g. endocrine
CC polyglandular syndrome, endocrinoma, and endocrine ophthalmopathy,
CC osteoclastoma and other bone remodelling disorders, bacterial infections
CC and sepsis. The polypeptides are also useful for identifying their
CC binding partners.
XX
SQ Sequence 64 AA;

Query Match 46.0%; Score 296; DB 19; Length 64;
Best Local Similarity 96.6%; Pred. No. 1.4e-26;
Matches 57; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRA 59
||||||||||||||||||||||||||||||||||| |||||||||||| ||||||||
Db 1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQXSRRWLQEGGQECXCKDWFLRA 59

RESULT 39
AAY11731
ID AAY11731 standard; Protein; 48 AA.
XX
AC AAY11731;
XX
DT 18-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID No: 331.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
PN WO9906550-A2.

XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01232.
XX
PR 01-AUG-1997; 97US-0905144.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153780/13.
DR N-PSDB; AAX40453.
XX
PT New isolated prostate-derived nucleic acids - used to develop
PT products which may have cytokine, immune regulatory, haematopoiesis
PT regulating, anti-inflammatory or tumour inhibition activity
XX
PS Claim 34; Page 511; 675pp; English.
XX
CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 48 AA;

  Query Match   34.9%; Score 225; DB 20; Length 48;
  Best Local Similarity   97.9%; Pred. No. 1.6e-18;
  Matches   46; Conservative   0; Mismatches   1; Indels   0; Gaps   0;

Qy   1 MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGG 47
              |||||||||||||||||||||||| ||||||||||||||||||||||
Db   1 MKVLISSLLLLLPLMLMSMVSSSLXPGVARGHRDRGQASRRWLQEGG 47

RESULT 40
AAU66308
ID AAU66308 standard; Protein; 191 AA.
XX
AC AAU66308;
XX
DT 27-FEB-2002 (first entry)
XX

DE Propionibacterium acnes immunogenic protein #27204.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
PR 02-JUN-2000; 2000US-208841P.
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59728.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Example 1; SEQ ID No 27503; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 191 AA;

Query Match 12.2%; Score 78.5; DB 22; Length 191;

```
  Best Local Similarity   22.4%;  Pred. No. 0.69;
  Matches   32;  Conservative   20;  Mismatches   38;  Indels   53;  Gaps    7;

Qy          18 SMVSSSLNPGVARGHRDR--GQAS-----------RRW-----LQEGGQECECKDWFLRA 59
               || : |: ||:    ::|  |: :            | |     :   ||    :|::|||
Db          10 SMAAESIAPGIVNQXKNRQMGETTSSRCARLTTHPRFWTHPTSIPGEGQRFRGEDFWLRA 69

Qy          60 PRRKFMTVSGLPKKQCPCDHFKGNVKKTRHQ--RHHRKPNKHSRACQQ------------ 105
               ||         ||:   | :    |: : |    ||| :    :| | :
Db          70 PR--------LPQLGPPSE----NLPQCRRSAARHHAQTGSAARRCMELEEAVLADDYFI 117

Qy         106 ---------FLKQCQLRSFALPL 119
                       |     ||:  :||
Db         118 ERRLYPNVDFYSGIVLRALGIPL 140
```

```
RESULT 41
AAP91996
ID   AAP91996 standard; protein; 70 AA.
XX
AC   AAP91996;
XX
DT   25-MAR-2003  (updated)
DT   05-MAR-1990  (first entry)
XX
DE   Part of chick vitamin D recptor.
XX
KW   Chick vitamin D receptor; cystein-rich DNA binding domain;
XX
OS   Gallus gallus.
XX
PN   WO8909223-A.
XX
PD   05-OCT-1989.
XX
PF   24-MAR-1989;   89WO-JP01238.
XX
PR   30-MAR-1988;   88US-0176107.
PR   05-OCT-1988;   88US-0253807.
PR   21-FEB-1989;   89US-0312763.
XX
PA   (ARCH-) ARCH DEV CORP.
XX
PI   Liao S,  Chang C;
XX
DR   WPI; 1989-309501/42.
XX
PT   New DNA encoding new androgen receptor and TR2 polypeptide(s) - able
PT   to bind DNA, and derived antibodies, useful for receptor assay and
PT   purification.
XX
PS   Disclosure; Fig 5; 60pp; English.
XX
CC   The sequence is part of the chick vitamin D receptor and is homologous
CC   with the cysteine-rich DNA binding domain of human androgen receptor,
CC   glucocorticoid receptor, mineralocorticoid receptor, progesterone
CC   receptor, TR2, rat AR, and v-erb A oncogene product.
```

```
CC   See also AAP91991 - AAP91995.
CC   (Updated on 25-MAR-2003 to correct PF field.)
CC   (Updated on 25-MAR-2003 to correct PR field.)
CC   (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence   70 AA;

  Query Match             11.4%;  Score 73.5;  DB 10;  Length 70;
  Best Local Similarity   35.5%;  Pred. No. 0.79;
  Matches   22;  Conservative    9;  Mismatches   12;  Indels   19;  Gaps    5;

Qy         50 CE-CKDWFLRAPRRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLK 108
              || || :| |: :|| |          ||   | |: | |:  |      :| :||:  ||
Db         20 CEGCKGFFRRSMKRKAMFT-------CP---FNGDCKITKDNR------RHCQACR--LK 61

Qy        109 QC 110
              :|
Db         62 RC 63


RESULT 42
AAR43657
ID   AAR43657 standard; Protein; 70 AA.
XX
AC   AAR43657;
XX
DT   16-MAY-1994  (first entry)
XX
DE   Chicken vitamin D receptor.
XX
KW   1,25-dihydroxyvitamin D3; receptor; recombinant protein production;
KW   insect host.
XX
OS   Gallus domesticus.
XX
PN   US5260199-A.
XX
PD   09-NOV-1993.
XX
PF   30-JUL-1991;   91US-0737736.
XX
PR   30-JUL-1991;   91US-0737736.
XX
PA   (WISC ) WISCONSIN ALUMNI RES FOUND.
XX
PI   Deluca HF,  Prahl JM,  Ross TK;
XX
DR   WPI; 1993-367874/46.
XX
PT   Recombinant prodn. of 1,25-di:hydroxy-vitamin=D3 receptor protein
PT   - using expression system comprising insect cell host and
PT   recombinant virus contg. foreign DNA
XX
PS   Disclosure; Columns 9-12; 13pp; English.
XX
CC   The 1,25-dihydroxyvitamin D3 receptor is recombinantly produced
CC   using insect host cells transformed with DNA coding for an animal
```

```
CC   (pref. human, rat, porcine or avian) vitamin D receptor. The coding
CC   sequence is incorporated into a recombinant baculovirus vector for
CC   transformation of the insect host. The chicken version of the coding
CC   sequence was published in McDonnell et al., Science 235; 1214-1217
CC   (1987).
XX
SQ   Sequence   70 AA;

  Query Match             11.4%;  Score 73.5;  DB 14;  Length 70;
  Best Local Similarity   35.5%;  Pred. No. 0.79;
  Matches   22;  Conservative    9;  Mismatches   12;  Indels   19;  Gaps    5;

Qy         50 CE-CKDWFLRAPRRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLK 108
              || || :| |: :|| |          ||    | |: | |:  |      :| :||:  ||
Db         20 CEGCKGFFRRSMKRKAMFT-------CP---FNGDCKITKDNR------RHCQACR--LK 61

Qy        109 QC 110
              :|
Db         62 RC 63


RESULT 43
AAO21337
ID   AAO21337 standard; Protein; 108 AA.
XX
AC   AAO21337;
XX
DT   05-AUG-2002  (first entry)
XX
DE   Arabidopsis thaliana KCP-like protein, SEQ ID NO 92.
XX
KW   Antimicrobial; transgenic; plant; potato snakin antimicrobial protein;
KW   GASA4; GASA5; GAST1 homologue; lysine- and cysteine- rich peptide;
KW   KCP-like polypeptide; modulating; disease resistance.
XX
OS   Arabidopsis thaliana.
XX
PN   WO200222821-A2.
XX
PD   21-MAR-2002.
XX
PF   13-SEP-2001; 2001WO-US28429.
XX
PR   13-SEP-2000; 2000US-232569P.
PR   11-SEP-2001; 2001US-0950933.
XX
PA   (PION-) PIONEER HI-BRED INT INC.
XX
PI   Simmons CR,  Navarro Acevedo PA;
XX
DR   WPI; 2002-425842/45.
XX
PT   New polynucleotide encoding lysine- and cysteine-rich peptides-like
PT   polypeptide useful for modulating the polypeptide level in a plant
PT   cell, enhancing disease resistance  -
XX
PS   Disclosure; Page 159; 163pp; English.
```

```
XX
CC   The invention relates to an isolated polynucleotide encoding a
CC   polypeptide which is related to potato snakin antimicrobial protein and
CC   GASA4 or GASA5 or GAST1 homologues, which is referred to as lysine- and
CC   cysteine- rich peptides (KCP)-like polypeptide, having a nucleotide
CC   sequence from 36 sequences of defined base pairs, given in the
CC   specification. A recombinant expression cassette comprising the isolated
CC   polynucleotide of the invention is useful for modulating the level of
CC   (KCP)-like polypeptides in a plant cell, where the level of (KCP)-like
CC   polypeptides is increased, and disease resistance is enhanced. This
CC   sequence represents a protein relating to the KCP-like proteins of the
CC   invention.
XX
SQ   Sequence   108 AA;

  Query Match             11.1%;  Score 71.5;  DB 23;  Length 108;
  Best Local Similarity   25.9%;  Pred. No. 2.3;
  Matches   29;  Conservative   18;  Mismatches   38;  Indels   27;  Gaps    7;

Qy          1 MKVLISSLLLL-LPLMLMSMVSSSLNPGVARG------HRDRGQASRRWLQEGGQECE-- 51
              ||:::| |:|  | |:  |: |::::     |          | |  :|    ||:||
Db          1 MKIIVSILVLASLLLISSSLASATISDAFGSGAVAPAPQSKDGPALEKWC---GQKCEGR 57

Qy         52 CKDWFLRAPRRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRAC 103
              ||:      : : :   |:  | | |      |    :       |||  ||
Db         58 CKE---AGMKDRCLKYCGICCKDCQC------VPSGTY------GNKHECAC 94


RESULT 44
ABG25331
ID   ABG25331 standard; Protein; 330 AA.
XX
AC   ABG25331;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #25322.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
```

```
DR   N-PSDB; AAS89518.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 55690; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   330 AA;

  Query Match             11.0%;  Score 71;  DB 22;  Length 330;
  Best Local Similarity   29.8%;  Pred. No. 9.7;
  Matches   28;  Conservative    5;  Mismatches   27;  Indels   34;  Gaps    6;

Qy         18 SMVSSSLNPG----------VARGHRDRGQASRRW--LQEGGQECECKDWFLRAPRRKFM 65
              | |  :  ||          :|  |  | ||   |  ||   |:|| |
Db         20 SRVPGTHGPGPADHGQPPCCMAGAHPPRPQA---WMLLQTHSQDCEGK------------ 64

Qy         66 TVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKH 99
                 |     ||| |   : | | |  ||  |: |
Db         65 --VGCGGIFCPCYH---HCKHTHHHHHH--PHHH 91


RESULT 45
AAW50896
ID   AAW50896 standard; Protein; 1798 AA.
XX
AC   AAW50896;
XX
DT   07-DEC-1998  (first entry)
XX
DE   Human laminin B2 chain.
XX
KW   Laminin; human; beta-amyloid; amyloidosis; Alzheimer's disease;
```

KW Down's syndrome; hereditary cerebral haemorrhage; inflammation;
KW malignancy; Familial Mediterranean Fever; multiple myeloma;
KW type II diabetes; prion disease; Creutzfeldt-Jacob disease; CJD;
KW Gertstmann-Straussler syndrome; kuru; scrapie; haemodialysis;
KW carpal tunnel syndrome; senile cardiac amyloid polyneuropathy;
KW Familial Amyloidotic Polyneuropathy; thyroid carcinoma; diagnosis;
KW therapy.
XX
OS Homo sapiens.
XX
PN WO9815179-A1.
XX
PD 16-APR-1998.
XX
PF 08-OCT-1997; 97WO-US18145.
XX
PR 08-OCT-1996; 96US-0027981.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Castillo G, Snow AD;
XX
DR WPI; 1998-240534/21.
XX
PT Use of laminin and fragments - for developing products for use in
PT the diagnosis and treatment of amyloid disease, e.g. Alzheimer's
PT disease or CJD
XX
PS Claim 15; Page 98-101; 132pp; English.
XX
CC This is the amino acid sequence of the human laminin B2 chain. The
CC primary object of the invention is to use laminin, laminin-derived
CC protein fragments and/or laminin-derived polypeptides as potent
CC inhibitors of amyloid formation, deposition, accumulation and/or
CC persistence in Alzheimer's disease and other amyloidoses. The
CC laminin products (see AAW50888-98) may include mouse or human laminin
CC A or A1 chain, laminin B1 or B2 chain, laminin A2 chain (merosin),
CC laminin G1 chain, the globular repeats of the laminin A1 chain and
CC the beta-amyloid binding domain of the laminin A chain. A claimed
CC method for treating an amyloid disease comprises administering a
CC polypeptide having a conformational similarity to a fragment of a
CC laminin protein. A method for diagnosing an amyloid disease
CC involves determining levels of laminin in a sample. Production
CC of laminin or its fourth globular repeat in vivo provides a method
CC for in vivo inhibition of beta-amyloid amyloidosis. The products
CC and methods can be used for the diagnosis, prognosis, monitoring
CC and treatment of amyloidoses such as Alzheimer's disease, Down's
CC syndrome and hereditary cerebral haemorrhage with amyloidosis of
CC the Dutch type (where the specific amyloid is the beta-amyloid
CC protein), the amyloidosis associated with chronic inflammation,
CC various forms of malignancy and Familial Mediterranean Fever (AA
CC amyloid or inflammation-association amyloidosis), the amyloidosis
CC associated with multiple myeloma and other B-cell abnormalities
CC (AL amyloid), the amyloidosis associated with type II diabetes
CC (amylin or islet amyloid), the amyloidosis associated with prion
CC diseases including Creutzfeldt-Jacob disease, Gertstmann-Straussler
CC syndrome, kuru and animal scrapie (PrP amyloid), the amyloidosis

CC associated with long-term haemodialysis and carpal tunnel syndrome
CC (beta 2-microglobulin amyloid), the amyloidosis associated with
CC senile cardiac amyloid and Familial Amyloidotic Polyneuropathy
CC (prealbumin or transthyretin amyloid), and the amyloidosis
CC associated with endocrine tumours such as medullary carcinoma of
CC the thyroid (variant of procalcitonin).
XX
SQ Sequence 1798 AA;

Query Match 11.0%; Score 71; DB 19; Length 1798;
Best Local Similarity 28.4%; Pred. No. 73;
Matches 27; Conservative 6; Mismatches 46; Indels 16; Gaps 4;

```
Qy          23 SLNPGVARGHRDR-----GQASRRWLQEGGQECE-CKDWFLRAPRRKFMTVSGLPKKQCP 76
               |  | |  || |      |          ||: || |   | | ||  :    |   : ||
Db         873 SCRPCVCNGHADECNTHTGACLGCRDHTGGEHCERCIAGFHRDPRLPY----GGQCRPCP 928

Qy          77 CDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQ 111
               |    |:      |||           || :  |:
Db         929 CPEGPGS------QRHFATSCHQDEYSQQIVCHCR 957
```

Search completed: February 12, 2004, 15:43:50
Job time : 42 secs